In light of the FDA approval of tofersen for SOD1-related ALS, what is your approach to counseling people who are presymptomatic genetic carriers of one of the monogenic ALS genes?   

What do you recommend for surveillance and when to start the “three R’s” (riluzole, radicava/edaravone, and relyvrio (sodium PB/TUDCA))?



Answer from: at Academic Institution